Drug Profile
Low molecular weight heparin buccal spray - Generex Biotechnology Corporation
Alternative Names: LMW heparin buccal spray; Low molecular weight heparin oral sprayLatest Information Update: 15 Jan 2013
Price :
$50
*
At a glance
- Originator Generex Biotechnology Corporation
- Class Low molecular weight heparins
- Mechanism of Action Antithrombin III stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Deep vein thrombosis
Most Recent Events
- 01 Jan 2013 Low molecular weight heparin buccal spray is available for licensing as of 01 Jan 2013. \(http://www.generex.com/\)
- 31 May 2004 No development reported - Phase-I for Deep vein thrombosis in Canada (Buccal)
- 14 May 2002 Phase-I clinical trials in Deep vein thrombosis in Canada (Buccal)